These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
120 related articles for article (PubMed ID: 25153418)
1. Aberrant hypermethylation of CTNNA1 gene is associated with higher IPSS risk in patients with myelodysplastic syndrome. Qian J; Chen XX; Qian W; Yang J; Wen XM; Ma JC; Deng ZQ; Qian Z; Zhang YY; Lin J Clin Chem Lab Med; 2014 Dec; 52(12):1859-65. PubMed ID: 25153418 [TBL] [Abstract][Full Text] [Related]
2. Methylation of CTNNA1 promoter: frequent but not an adverse prognostic factor in acute myeloid leukemia. Chen XX; Lin J; Qian J; Qian W; Yang J; Ma JC; Deng ZQ; An C; Tang CY; Qian Z; Liu Q Leuk Res; 2014 May; 38(5):613-8. PubMed ID: 24685333 [TBL] [Abstract][Full Text] [Related]
3. Aberrant methylation of DNA-damage-inducible transcript 3 promoter is a common event in patients with myelodysplastic syndrome. Lin J; Wang YL; Qian J; Yao DM; Zhu ZH; Qian Z; Xu WR Leuk Res; 2010 Aug; 34(8):991-4. PubMed ID: 20116099 [TBL] [Abstract][Full Text] [Related]
4. Progressive chromatin repression and promoter methylation of CTNNA1 associated with advanced myeloid malignancies. Ye Y; McDevitt MA; Guo M; Zhang W; Galm O; Gore SD; Karp JE; Maciejewski JP; Kowalski J; Tsai HL; Gondek LP; Tsai HC; Wang X; Hooker C; Smith BD; Carraway HE; Herman JG Cancer Res; 2009 Nov; 69(21):8482-90. PubMed ID: 19826047 [TBL] [Abstract][Full Text] [Related]
5. Prognostic relevance of aberrant SOCS-1 gene promoter methylation in myelodysplastic syndromes patients. Chaubey R; Sazawal S; Mahapatra M; Chhikara S; Saxena R Int J Lab Hematol; 2015 Apr; 37(2):265-71. PubMed ID: 25123164 [TBL] [Abstract][Full Text] [Related]
6. Aberrant promoter methylation of Dab2 gene in myelodysplastic syndrome. Yang Y; Zhang Q; Xu F; Chang C; Li X Eur J Haematol; 2012 Dec; 89(6):469-77. PubMed ID: 23005040 [TBL] [Abstract][Full Text] [Related]
7. Methylation of DAPK1 promoter: frequent but not an adverse prognostic factor in myelodysplastic syndrome. Qian J; Yao DM; Lin J; Wang YL; Han LX; Xu WR; Wu CY Int J Lab Hematol; 2010 Feb; 32(1 Pt 2):74-81. PubMed ID: 19196380 [TBL] [Abstract][Full Text] [Related]
8. Methylation status of fragile histidine triad (FHIT) gene and its clinical impact on prognosis of patients with myelodysplastic syndrome. Lin J; Yao DM; Qian J; Wang YL; Han LX; Jiang YW; Fei X; Cen JN; Chen ZX Leuk Res; 2008 Oct; 32(10):1541-5. PubMed ID: 18367246 [TBL] [Abstract][Full Text] [Related]
9. Chromosome 5q deletion and epigenetic suppression of the gene encoding alpha-catenin (CTNNA1) in myeloid cell transformation. Liu TX; Becker MW; Jelinek J; Wu WS; Deng M; Mikhalkevich N; Hsu K; Bloomfield CD; Stone RM; DeAngelo DJ; Galinsky IA; Issa JP; Clarke MF; Look AT Nat Med; 2007 Jan; 13(1):78-83. PubMed ID: 17159988 [TBL] [Abstract][Full Text] [Related]
10. CTNNA1 hypermethylation, a frequent event in acute myeloid leukemia, is independently associated with an adverse outcome. Li M; Gao L; Li Z; Sun J; Zhang H; Duan H; Ma Y; Wang C Oncotarget; 2016 May; 7(21):31454-65. PubMed ID: 27129146 [TBL] [Abstract][Full Text] [Related]
11. [Alteration of methylation status of fragile histidine triad gene promoter in patients with myelodysplastic syndrome]. Yao DM; Qian J; Xu WR; Lin J; Jiang YW; Fei X; Han LX; Wang Y; Cen JN; Chen ZX Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2008 Feb; 25(1):36-9. PubMed ID: 18247301 [TBL] [Abstract][Full Text] [Related]
12. ID4 methylation predicts high risk of leukemic transformation in patients with myelodysplastic syndrome. Wang H; Wang XQ; Xu XP; Lin GW Leuk Res; 2010 May; 34(5):598-604. PubMed ID: 19853913 [TBL] [Abstract][Full Text] [Related]
13. Promoter hypermethylation of p15INK4B, HIC1, CDH1, and ER is frequent in myelodysplastic syndrome and predicts poor prognosis in early-stage patients. Aggerholm A; Holm MS; Guldberg P; Olesen LH; Hokland P Eur J Haematol; 2006 Jan; 76(1):23-32. PubMed ID: 16343268 [TBL] [Abstract][Full Text] [Related]
14. Abnormal methylation of the sex-determining region Y-box 17 (SOX17) promoter predicts poor prognosis in myelodysplastic syndrome. Fan R; Zhao XL; Wang H; He HY; Peng ZP; Yang B; Han T; Wang W; Wang XQ; Lin GW Clin Lab; 2014; 60(9):1465-74. PubMed ID: 25291942 [TBL] [Abstract][Full Text] [Related]
15. Hypermethylation of DLX4 predicts poor clinical outcome in patients with myelodysplastic syndrome. Zhang TJ; Zhou JD; Yang DQ; Wang YX; Yao DM; Ma JC; Wen XM; Guo H; Lin J; Qian J Clin Chem Lab Med; 2016 May; 54(5):865-71. PubMed ID: 26485746 [TBL] [Abstract][Full Text] [Related]
16. [Study on prognostic significances of different cytogenetic risk categories in patients with primary myelodysplastic syndromes]. Qu SQ; Liu XP; Xu ZF; Zhang Y; Qin TJ; Zhang TJ; Cui R; Hao YS; Xiao ZJ Zhonghua Xue Ye Xue Za Zhi; 2011 Dec; 32(12):819-24. PubMed ID: 22339954 [TBL] [Abstract][Full Text] [Related]
17. [Methylation status of ZO-1 gene in patients with myelodysplastic syndrome]. Kang HY; Wang C; Dou LP; Qing Y; Han XP; Sun JF; Liu CH; Lu XC; Liu Y; Yu L Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Feb; 16(1):70-3. PubMed ID: 18315903 [TBL] [Abstract][Full Text] [Related]
18. The lower risk MDS patient at risk of rapid progression. Mittelman M; Oster HS; Hoffman M; Neumann D Leuk Res; 2010 Dec; 34(12):1551-5. PubMed ID: 20573398 [TBL] [Abstract][Full Text] [Related]
19. [Significance of methylation status of zo-1 gene in differential diagnosis for myelodysplastic syndrome]. Kang HY; Wang XR; Wang LL; Wang C; Cen J; Gao L; Liu Y; Li YH; Yu L Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Feb; 19(1):76-80. PubMed ID: 21362226 [TBL] [Abstract][Full Text] [Related]
20. [Study of aberrant p73 promoter methylation in patients with myelodysplastic syndrome]. Zhao YS; Yang R; Gu SC; Guo J; Zhang X; Wu LY; Li X; Chang CK Zhonghua Xue Ye Xue Za Zhi; 2012 Oct; 33(10):847-51. PubMed ID: 23384909 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]